Common Contracts
3 similar Stock Repurchase Agreement contracts by Syneos Health, Inc.
STOCK REPURCHASE AGREEMENTStock Repurchase Agreement • June 4th, 2021 • Syneos Health, Inc. • Services-commercial physical & biological research • New York
THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of June 1, 2021 by and between Syneos Health, Inc., a Delaware corporation (the “Company”), Thomas H. Lee Equity Fund VII, L.P., Thomas H. Lee Parallel Fund VII, L.P., THL Executive Fund VII, L.P., THL Fund VII Coinvestment Partners, L.P., THL Equity Fund VII Investors (inVentiv), L.P., Thomas H. Lee Equity Fund VI (2019), L.P., THL Fund VI (2019) Coinvestment Partners, L.P., THL Managers VI, LLC and THL Managers VII, LLC (collectively, the “THL Funds”) and Double Eagle Investor Holdings, L.P. and Advent International GPE VIII-C Limited Partnership (together, the “Advent Funds”, and collectively with the THL Funds, the “Sellers”).
STOCK REPURCHASE AGREEMENTStock Repurchase Agreement • May 5th, 2021 • Syneos Health, Inc. • Services-commercial physical & biological research • New York
THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of April 30, 2021 by and between Syneos Health, Inc., a Delaware corporation (the “Company”), Thomas H. Lee Equity Fund VII, L.P., Thomas H. Lee Parallel Fund VII, L.P., THL Executive Fund VII, L.P., THL Fund VII Coinvestment Partners, L.P., THL Equity Fund VII Investors (inVentiv), L.P., Thomas H. Lee Equity Fund VI (2019), L.P., THL Fund VI (2019) Coinvestment Partners, L.P., THL Managers VI, LLC and THL Managers VII, LLC (collectively, the “THL Funds”) and Double Eagle Investor Holdings, L.P. and Advent International GPE VIII-C Limited Partnership (together, the “Advent Funds”, and collectively with the THL Funds, the “Sellers”).
STOCK REPURCHASE AGREEMENTStock Repurchase Agreement • March 3rd, 2021 • Syneos Health, Inc. • Services-commercial physical & biological research • New York
THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of February 26, 2021 by and between Syneos Health, Inc., a Delaware corporation (the “Company”), Thomas H. Lee Equity Fund VII, L.P., Thomas H. Lee Parallel Fund VII, L.P., THL Executive Fund VII, L.P., THL Fund VII Coinvestment Partners, L.P., THL Equity Fund VII Investors (inVentiv), L.P., Thomas H. Lee Equity Fund VI (2019), L.P., THL Fund VI (2019) Coinvestment Partners, L.P., THL Managers VI, LLC and THL Managers VII, LLC (collectively, the “THL Funds”) and Double Eagle Investor Holdings, L.P. and Advent International GPE VIII-C Limited Partnership (together, the “Advent Funds”, and collectively with the THL Funds, the “Sellers”).
